186551-70-2

Basic information

• Product Name: tert-Butyl 3-Methyl-1H-pyrazole-1-carboxylate
• Synonyms: tert-Butyl 3-Methyl-1H-pyrazole-1-carboxylate;tert-Butyl 3-Methylpyrazole-1-carboxylate
• CAS NO: 186551-70-2
• Molecular Formula: C9H14N2O2
• Molecular Weight: 182.21966
• Mol File: 186551-70-2.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: tert-Butyl 3-Methyl-1H-pyrazole-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl 3-Methyl-1H-pyrazole-1-carboxylate(186551-70-2)
• EPA Substance Registry System: tert-Butyl 3-Methyl-1H-pyrazole-1-carboxylate(186551-70-2)

Safety Data

• Hazardous Substances Data: 186551-70-2(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
Tert-Butyl 3-Methyl-1H-pyrazole-1-carboxylate serves as a valuable building block in organic synthesis, facilitating the creation of a wide range of chemical compounds. Its unique structure allows for various chemical reactions, making it a useful intermediate in the synthesis process.
Used in Pharmaceutical Industry:
In the pharmaceutical sector, Tert-Butyl 3-Methyl-1H-pyrazole-1-carboxylate is utilized as a key component in the development of new drugs. Its chemical properties enable it to be incorporated into drug molecules, potentially enhancing their therapeutic effects and pharmacological profiles.
Used in Agrochemical Industry:
Tert-Butyl 3-Methyl-1H-pyrazole-1-carboxylate also finds application in the agrochemical industry, where it is employed as a building block for the synthesis of various agrochemicals. Its incorporation into these compounds can contribute to the development of more effective and targeted agrochemical products.
Used as a Reagent:
Furthermore, Tert-Butyl 3-Methyl-1H-pyrazole-1-carboxylate functions as a reagent in the production of other compounds. Its ability to participate in various chemical reactions makes it a valuable tool in the synthesis of a diverse array of products across different industries.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 1453-58-3 3-Methylpyrazole 

Downstream Products

• 186551-71-3 7-methoxynaphthalene-2-sulfonic acid [1-(3-cyanobenzyl)-2-oxopyrrolidin-3-(S)-yl](N-tert-butyloxycarbonylpyrazol-3-ylmethyl)amide 
• 186551-69-9 tert-butyl 3-(bromomethyl)-1H-pyrazole-1-carboxylate 

Relevant articles and documents

PHENOXYMETHYL DERIVATIVES

The invention provides novel compounds having the general formula (I), wherein RA, RB, RC, RC1 and W are as defined herein, compositions including the compounds and methods of using the compounds.

NOVEL ANTIVIRAL PYRROLOPYRIDINE DERIVATIVES AND METHOD FOR PREPARING THE SAME

The present invention relates to a pyrrolopyridine derivative represented by the Chemical Formula I, and a racemate or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and relates to an antiviral composition including the same as an active ingredient. The compound of the Chemical Formula I has excellent antiviral activity and selectivity for wild type and resistant HIV-1, and thereby is useful as a therapeutic agent for acquired immune deficiency syndrome (AIDS).

NOVEL ANTIVIRAL PYRROLOPYRIDINE DERIVATIVE AND A PRODUCTION METHOD FOR SAME

The present invention relates to a pyrrolopyridine derivative represented by the Chemical Formula I, and a racemate or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and relates to an antiviral composition including the same as an active ingredient. The compound of the Chemical Formula I has excellent antiviral activity and selectivity for wild type and resistant HIV-1, and thereby is useful as a therapeutic agent for acquired immune deficiency syndrome (AIDS).

BIARYL COMPOUNDS USEFUL AS AGONISTS OF THE GPR38 RECEPTOR

The present invention relates to novel biaryl derivatives such as compounds of formula (I), which have activity as agonists of the GPR38 receptor and the use of such compounds or pharmaceutical compositions thereof in the treatment of gastrointestinal dis

ACE-2 modulating compounds and methods of use thereof

ACE-2 modulating compounds for the treatment of body weight disorders are disclosed. Methods of using the compounds and pharmaceutical compositions containing the compounds are also claimed.

Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa

The discovery of a series of non-peptide factor Xa (FXa) inhibitors incorporating 3-(s)-amino-2-pyrrolidinone as a central template is described. After identifying compound 4, improvements in in vitro potency involved modifications of the liphophilic group and optimizing the angle of presentation of the amidine group to the S1 pocket of FXa. These studies ultimately led to compound RPR120844, a potent inhibitor of FXa (K1 = 7 nM) which shows selectivity for FXa over trypsin, thrombin, and several fibrinolytic serine proteinases. RPR120844 is an effective anticoagulant in both the rat model of FeCl2-induced carotid artery thrombosis and the rabbit model of jugular vein thrombus formation.